• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏肥大的新兴治疗靶点。

Emerging therapeutic targets for cardiac hypertrophy.

机构信息

The Frick Center for Heart Failure and Arrhythmia, The Dorothy M. Davis Heart and Lung Research Institute, the Ohio State University Wexner Medical Center, Columbus, OH, USA.

Department of Biomedical Engineering, College of Engineering, the Ohio State University, Columbus, OH, USA.

出版信息

Expert Opin Ther Targets. 2022 Jan;26(1):29-40. doi: 10.1080/14728222.2022.2031974. Epub 2022 Jan 27.

DOI:10.1080/14728222.2022.2031974
PMID:35076342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885901/
Abstract

INTRODUCTION

Cardiac hypertrophy is associated with adverse outcomes across cardiovascular disease states. Despite strides over the last three decades in identifying molecular and cellular mechanisms driving hypertrophy, the link between pathophysiological stress stimuli and specific myocyte/heart growth profiles remains unclear. Moreover, the optimal strategy for preventing pathology in the setting of hypertrophy remains controversial.

AREAS COVERED

This review discusses molecular mechanisms underlying cardiac hypertrophy with a focus on factors driving the orientation of myocyte growth and the impact on heart function. We highlight recent work showing a novel role for the spectrin-based cytoskeleton, emphasizing regulation of myocyte dimensions but not hypertrophy per se. Finally, we consider opportunities for directing the orientation of myocyte growth in response to hypertrophic stimuli as an alternative therapeutic approach. Relevant publications on the topic were identified through Pubmed with open-ended search dates.

EXPERT OPINION

To define new therapeutic avenues, more precision is required when describing changes in myocyte and heart structure/function in response to hypertrophic stimuli. Recent developments in computational modeling of hypertrophic networks, in concert with more refined experimental approaches will catalyze translational discovery to advance the field and further our understanding of cardiac hypertrophy and its relationship with heart disease.

摘要

简介

心肌肥厚与心血管疾病状态的不良结局相关。尽管在过去三十年中,人们在确定驱动肥厚的分子和细胞机制方面取得了进展,但病理生理应激刺激与特定心肌/心脏生长特征之间的联系仍不清楚。此外,在肥厚的情况下预防病理学的最佳策略仍存在争议。

涵盖领域

本文讨论了心肌肥厚的分子机制,重点介绍了驱动心肌生长方向的因素及其对心脏功能的影响。我们强调了最近的工作,表明基于血影蛋白的细胞骨架在调节心肌细胞尺寸方面具有新的作用,但本身并不引起心肌肥厚。最后,我们考虑了在应对肥厚刺激时指导心肌生长方向的机会,作为一种替代的治疗方法。通过 Pubmed 进行了开放式搜索日期的主题相关出版物的识别。

专家意见

为了确定新的治疗途径,在描述对肥厚刺激的心肌和心脏结构/功能的变化时,需要更精确。在肥厚网络的计算模型方面的最新进展,以及更精细的实验方法,将促进转化发现,推动该领域的发展,并进一步加深我们对心肌肥厚及其与心脏病关系的理解。

相似文献

1
Emerging therapeutic targets for cardiac hypertrophy.心脏肥大的新兴治疗靶点。
Expert Opin Ther Targets. 2022 Jan;26(1):29-40. doi: 10.1080/14728222.2022.2031974. Epub 2022 Jan 27.
2
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?心脏肥大的多种分子信号级联:能否澄清混乱局面?
Pharmacol Res. 2010 Nov;62(5):365-83. doi: 10.1016/j.phrs.2010.07.003. Epub 2010 Jul 17.
3
Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure.心脏肥大向心力衰竭转变的分子机制。
Circ J. 2008;72 Suppl A:A13-6. doi: 10.1253/circj.cj-08-0481. Epub 2008 Sep 5.
4
Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure.信号小体调控的血清反应因子磷酸化决定心肌细胞的生长宽度与长度之比,作为心力衰竭的治疗靶点。
Circulation. 2020 Dec;142(22):2138-2154. doi: 10.1161/CIRCULATIONAHA.119.044805. Epub 2020 Sep 16.
5
CaMKII exacerbates heart failure progression by activating class I HDACs.CaMKII 通过激活 I 类 HDACs 加剧心力衰竭的进展。
J Mol Cell Cardiol. 2020 Dec;149:73-81. doi: 10.1016/j.yjmcc.2020.09.007. Epub 2020 Sep 22.
6
Calcineurin Aβ-Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy.钙调神经磷酸酶 Aβ 特异性锚定赋予病理性心肌细胞肥大中的同种型特异性区室化和功能。
Circulation. 2020 Sep 8;142(10):948-962. doi: 10.1161/CIRCULATIONAHA.119.044893. Epub 2020 Jul 2.
7
Kv4.3 expression abrogates and reverses norepinephrine-induced myocyte hypertrophy by CaMKII inhibition.Kv4.3 表达通过抑制 CaMKII 来消除和逆转去甲肾上腺素引起的心肌细胞肥大。
J Mol Cell Cardiol. 2019 Jan;126:77-85. doi: 10.1016/j.yjmcc.2018.11.011. Epub 2018 Nov 18.
8
ATF6 Regulates Cardiac Hypertrophy by Transcriptional Induction of the mTORC1 Activator, Rheb.ATF6 通过转录诱导 mTORC1 激活剂 Rheb 调节心脏肥厚。
Circ Res. 2019 Jan 4;124(1):79-93. doi: 10.1161/CIRCRESAHA.118.313854.
9
Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.量化心肌细胞肥大差异调节的表型筛选确定了CITED4对心肌细胞伸长的调节作用。
J Mol Cell Cardiol. 2014 Jul;72:74-84. doi: 10.1016/j.yjmcc.2014.02.013. Epub 2014 Mar 5.
10
Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.锚定的 p90 核糖体 S6 激酶 3 对于心肌细胞肥大是必需的。
Circ Res. 2013 Jan 4;112(1):128-39. doi: 10.1161/CIRCRESAHA.112.276162. Epub 2012 Sep 20.

引用本文的文献

1
20-HETE mediates Ang II-induced cardiac hypertrophy via ROS and Ca signaling in H9c2 cells.20-羟基二十碳四烯酸(20-HETE)通过活性氧(ROS)和钙信号传导介导血管紧张素II(Ang II)诱导的H9c2细胞肥大。
Sci Rep. 2025 Jan 17;15(1):2342. doi: 10.1038/s41598-025-85992-2.
2
USP20 deletion promotes eccentric cardiac remodeling in response to pressure overload and increases mortality.USP20 缺失促进了压力超负荷反应中心肌的重塑,并增加了死亡率。
Am J Physiol Heart Circ Physiol. 2024 Nov 1;327(5):H1257-H1271. doi: 10.1152/ajpheart.00329.2024. Epub 2024 Oct 4.
3
Reduced DNMT1 levels induce cell apoptosis via upregulation of METTL3 in cardiac hypertrophy.

本文引用的文献

1
Ca/calmodulin kinase II-dependent regulation of β-spectrin modulates cardiac fibroblast gene expression, proliferation, and contractility.钙/钙调蛋白激酶 II 依赖性调节 β- spectrin 调节心脏成纤维细胞基因表达、增殖和收缩性。
J Biol Chem. 2021 Jul;297(1):100893. doi: 10.1016/j.jbc.2021.100893. Epub 2021 Jun 18.
2
A peptide of the N terminus of GRK5 attenuates pressure-overload hypertrophy and heart failure.GRK5 N 端肽可减轻压力超负荷引起的心肌肥厚和心力衰竭。
Sci Signal. 2021 Mar 30;14(676):eabb5968. doi: 10.1126/scisignal.abb5968.
3
A peptide of the amino-terminus of GRK2 induces hypertrophy and yet elicits cardioprotection after pressure overload.
DNMT1水平降低通过上调METTL3诱导心肌肥大中的细胞凋亡。
Heliyon. 2024 Jan 17;10(3):e24572. doi: 10.1016/j.heliyon.2024.e24572. eCollection 2024 Feb 15.
4
Finding New Targets for the Treatment of Heart Failure: Endoplasmic Reticulum Stress and Autophagy.寻找心力衰竭治疗的新靶点:内质网应激与自噬
J Cardiovasc Transl Res. 2023 Dec;16(6):1349-1356. doi: 10.1007/s12265-023-10410-9. Epub 2023 Jul 11.
5
Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy.虚拟药物筛选揭示了心肌细胞肥大的上下文相关抑制作用。
Br J Pharmacol. 2023 Nov;180(21):2721-2735. doi: 10.1111/bph.16163. Epub 2023 Jul 5.
6
Effects of Obesity and Diabesity on Ventricular Muscle Structure and Function in the Zucker Rat.肥胖和糖尿病肥胖对Zucker大鼠心室肌结构和功能的影响。
Life (Basel). 2022 Aug 11;12(8):1221. doi: 10.3390/life12081221.
7
Upregulation of Phospholipase C Gene Expression Due to Norepinephrine-Induced Hypertrophic Response.由于去甲肾上腺素诱导的肥大反应导致磷脂酶 C 基因表达上调。
Cells. 2022 Aug 11;11(16):2488. doi: 10.3390/cells11162488.
8
Upregulation of key genes Eln and Tgfb3 were associated with the severity of cardiac hypertrophy.关键基因 Eln 和 Tgfb3 的上调与心脏肥大的严重程度相关。
BMC Genomics. 2022 Aug 14;23(1):592. doi: 10.1186/s12864-022-08778-0.
9
Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.钙蛋白酶作为心肌肥厚的潜在治疗靶点。
Int J Mol Sci. 2022 Apr 7;23(8):4103. doi: 10.3390/ijms23084103.
GRK2 氨基末端的一种肽可引起心肌肥厚,而在压力超负荷后可引起心脏保护。
J Mol Cell Cardiol. 2021 May;154:137-153. doi: 10.1016/j.yjmcc.2021.01.004. Epub 2021 Feb 4.
4
Context-specific network modeling identifies new crosstalk in β-adrenergic cardiac hypertrophy.语境特定网络建模鉴定出β-肾上腺素能心脏肥大中的新串扰。
PLoS Comput Biol. 2020 Dec 18;16(12):e1008490. doi: 10.1371/journal.pcbi.1008490. eCollection 2020 Dec.
5
Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.新兴的心律失常治疗靶点:STAT3 在调节心脏成纤维细胞功能中的作用。
Expert Opin Ther Targets. 2021 Jan;25(1):63-73. doi: 10.1080/14728222.2021.1849145. Epub 2020 Nov 23.
6
Osteoprotegerin prompts cardiomyocyte hypertrophy via autophagy inhibition mediated by FAK/BECLIN1 pathway.骨保护素通过 FAK/BECLIN1 通路介导的自噬抑制促进心肌细胞肥大。
Life Sci. 2021 Jan 1;264:118550. doi: 10.1016/j.lfs.2020.118550. Epub 2020 Oct 6.
7
A multiscale model of cardiac concentric hypertrophy incorporating both mechanical and hormonal drivers of growth.一种包含机械和激素生长驱动因素的心脏向心性肥厚的多尺度模型。
Biomech Model Mechanobiol. 2021 Feb;20(1):293-307. doi: 10.1007/s10237-020-01385-6. Epub 2020 Sep 24.
8
Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure.信号小体调控的血清反应因子磷酸化决定心肌细胞的生长宽度与长度之比,作为心力衰竭的治疗靶点。
Circulation. 2020 Dec;142(22):2138-2154. doi: 10.1161/CIRCULATIONAHA.119.044805. Epub 2020 Sep 16.
9
Role of FAK signaling in chagasic cardiac hypertrophy.FAK 信号通路在恰加斯心脏病心肌肥厚中的作用。
Braz J Infect Dis. 2020 Sep-Oct;24(5):386-397. doi: 10.1016/j.bjid.2020.08.007. Epub 2020 Sep 12.
10
KR-39038, a Novel GRK5 Inhibitor, Attenuates Cardiac Hypertrophy and Improves Cardiac Function in Heart Failure.新型GRK5抑制剂KR-39038可减轻心力衰竭中的心肌肥厚并改善心脏功能。
Biomol Ther (Seoul). 2020 Sep 1;28(5):482-489. doi: 10.4062/biomolther.2020.129.